Fragment-Based Drug Discovery - Couverture rigide

Couverture rigide

ISBN 10 : 1849739080 ISBN 13 : 9781849739085

Editeur : Royal Society of Chemistry, 2015

Synopsis

This book will prove to be an invaluable resource for medicinal chemists working in academia and industry, as well as anyone interested in drug discovery techniques.

A propos du livre

Biographie de l'auteur

Daniel A. Erlanson is the co-founder of Carmot Therapeutics, a small-molecule drug discovery company applying fragment-based approaches to a variety of therapeutic targets. Prior to Carmot, Dr. Erlanson spent a decade developing fragment-based drug discovery technologies at Sunesis Pharmaceuticals, where he worked since the company's inception. Before joining Sunesis, he was an NIH postdoctoral fellow with Dr. James A. Wells at Genentech. Dr. Erlanson earned his Ph.D. in chemistry from Harvard University in the laboratory of Gregory L. Verdine and his B.A. in chemistry from Carleton College. Wolfgang Jahnke is a Senior Research at the Novartis Institutes for Biomedical Research in Basel, Switzerland, where he leads the Fragment-Based Screening technology platform. He has received several honors, among them the appointment as Scientific Expert, and the Leading Scientist Award. Dr. Jahnke received his PhD from the TU Munchen, working with Horst Kessler on the development and application of novel NMR methods. Prior to joining Novartis, he worked with Peter Wright at the Scripps Research Institute in La Jolla.

Présentation de l'éditeur

Fragment-based drug discovery is a rapidly evolving area of research, which has recently seen new applications in areas such as epigenetics, GPCRs and the identification of novel allosteric binding pockets. The first fragment-derived drug was recently approved for the treatment of melanoma. It is hoped that this approval is just the beginning of the many drugs yet to be discovered using this fascinating technique. This book is written from a Chemist's perspective and comprehensively assesses the impact of fragment-based drug discovery on a wide variety of areas of medicinal chemistry. It will prove to be an invaluable resource for medicinal chemists working in academia and industry, as well as anyone interested in novel drug discovery techniques.

Détails de l'édition

• Éditeur: Royal Society of Chemistry
• Date d'édition: 2015
• Langue: anglais
• ISBN 10: 1849739080
• ISBN 13: 9781849739085
• Reliure: Relié
• Numéro d'édition: 1
• Nombre de pages: 314
• Éditeur: Howard Steven, Abell Chris
• Coordonnées du fabricant: non disponible
• Personne responsable: non disponible